Global RNA Interference (RNAi) Market to Reach $356.9 Billion by 2030

ReportLinker

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet.

New York, March 15, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global RNA Interference (RNAi) Industry" - https://www.reportlinker.com/p06051396/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global RNA Interference (RNAi) Market to Reach $356.9 Billion by 2030

In the changed post COVID-19 business landscape, the global market for RNA Interference (RNAi) estimated at US$99.9 Billion in the year 2022, is projected to reach a revised size of US$356.9 Billion by 2030, growing at aCAGR of 17.3% over the period 2022-2030. Oncology, one of the segments analyzed in the report, is projected to record 20.2% CAGR and reach US$152.8 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Ocular Disorders segment is readjusted to a revised 18.2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $26.9 Billion, While China is Forecast to Grow at 24.4% CAGR

The RNA Interference (RNAi) market in the U.S. is estimated at US$26.9 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$98.5 Billion by the year 2030 trailing a CAGR of 24.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.6% and 15% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 12.6% CAGR.

Select Competitors (Total 12 Featured)
- Alnylam Pharmaceuticals, Inc.
- Benitec BioPharma
- Ionis Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- Qiagen, Inc.
- Quark Pharmaceuticals, Inc.
- Silence Therapeutics PLC


Read the full report: https://www.reportlinker.com/p06051396/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
RNA Interference (RNAi) - Global Key Competitors Percentage
Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for RNA
Interference (RNAi) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 2: World Historic Review for RNA Interference (RNAi) by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 3: World 16-Year Perspective for RNA Interference (RNAi)
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2014, 2023 & 2030

Table 4: World Recent Past, Current & Future Analysis for Drug
Discovery & Development by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR

Table 5: World Historic Review for Drug Discovery & Development
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 6: World 16-Year Perspective for Drug Discovery &
Development by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2014, 2023 & 2030

Table 7: World Recent Past, Current & Future Analysis for
Therapeutics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 8: World Historic Review for Therapeutics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 9: World 16-Year Perspective for Therapeutics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 10: World Recent Past, Current & Future Analysis for
Other Applications by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 11: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 12: World 16-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 13: World Recent Past, Current & Future Analysis for
Oncology by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 14: World Historic Review for Oncology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 15: World 16-Year Perspective for Oncology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030

Table 16: World Recent Past, Current & Future Analysis for
Ocular Disorders by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 17: World Historic Review for Ocular Disorders by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 18: World 16-Year Perspective for Ocular Disorders by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 19: World Recent Past, Current & Future Analysis for
Respiratory Disorders by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR

Table 20: World Historic Review for Respiratory Disorders by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 21: World 16-Year Perspective for Respiratory Disorders
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 22: World Recent Past, Current & Future Analysis for
Liver Diseases by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 23: World Historic Review for Liver Diseases by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 24: World 16-Year Perspective for Liver Diseases by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 25: World Recent Past, Current & Future Analysis for
Neuronal Disorders by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 26: World Historic Review for Neuronal Disorders by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 27: World 16-Year Perspective for Neuronal Disorders by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 28: World Recent Past, Current & Future Analysis for
Other Therapeutics by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 29: World Historic Review for Other Therapeutics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 30: World 16-Year Perspective for Other Therapeutics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 31: World RNA Interference (RNAi) Market Analysis of
Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

UNITED STATES
RNA Interference (RNAi) Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United States for 2023 (E)
Table 32: USA Recent Past, Current & Future Analysis for RNA
Interference (RNAi) by Application - Drug Discovery &
Development, Therapeutics and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 33: USA Historic Review for RNA Interference (RNAi) by
Application - Drug Discovery & Development, Therapeutics and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 34: USA 16-Year Perspective for RNA Interference (RNAi)
by Application - Percentage Breakdown of Value Sales for Drug
Discovery & Development, Therapeutics and Other Applications
for the Years 2014, 2023 & 2030

Table 35: USA Recent Past, Current & Future Analysis for RNA
Interference (RNAi) by Therapeutics - Oncology, Ocular
Disorders, Respiratory Disorders, Liver Diseases, Neuronal
Disorders and Other Therapeutics - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR

Table 36: USA Historic Review for RNA Interference (RNAi) by
Therapeutics - Oncology, Ocular Disorders, Respiratory
Disorders, Liver Diseases, Neuronal Disorders and Other
Therapeutics Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 37: USA 16-Year Perspective for RNA Interference (RNAi)
by Therapeutics - Percentage Breakdown of Value Sales for
Oncology, Ocular Disorders, Respiratory Disorders, Liver
Diseases, Neuronal Disorders and Other Therapeutics for the
Years 2014, 2023 & 2030

CANADA
Table 38: Canada Recent Past, Current & Future Analysis for RNA
Interference (RNAi) by Application - Drug Discovery &
Development, Therapeutics and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 39: Canada Historic Review for RNA Interference (RNAi) by
Application - Drug Discovery & Development, Therapeutics and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 40: Canada 16-Year Perspective for RNA Interference
(RNAi) by Application - Percentage Breakdown of Value Sales for
Drug Discovery & Development, Therapeutics and Other
Applications for the Years 2014, 2023 & 2030

Table 41: Canada Recent Past, Current & Future Analysis for RNA
Interference (RNAi) by Therapeutics - Oncology, Ocular
Disorders, Respiratory Disorders, Liver Diseases, Neuronal
Disorders and Other Therapeutics - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR

Table 42: Canada Historic Review for RNA Interference (RNAi) by
Therapeutics - Oncology, Ocular Disorders, Respiratory
Disorders, Liver Diseases, Neuronal Disorders and Other
Therapeutics Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 43: Canada 16-Year Perspective for RNA Interference
(RNAi) by Therapeutics - Percentage Breakdown of Value Sales
for Oncology, Ocular Disorders, Respiratory Disorders, Liver
Diseases, Neuronal Disorders and Other Therapeutics for the
Years 2014, 2023 & 2030

JAPAN
RNA Interference (RNAi) Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Japan for 2023 (E)
Table 44: Japan Recent Past, Current & Future Analysis for RNA
Interference (RNAi) by Application - Drug Discovery &
Development, Therapeutics and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 45: Japan Historic Review for RNA Interference (RNAi) by
Application - Drug Discovery & Development, Therapeutics and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 46: Japan 16-Year Perspective for RNA Interference (RNAi)
by Application - Percentage Breakdown of Value Sales for Drug
Discovery & Development, Therapeutics and Other Applications
for the Years 2014, 2023 & 2030

Table 47: Japan Recent Past, Current & Future Analysis for RNA
Interference (RNAi) by Therapeutics - Oncology, Ocular
Disorders, Respiratory Disorders, Liver Diseases, Neuronal
Disorders and Other Therapeutics - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR

Table 48: Japan Historic Review for RNA Interference (RNAi) by
Therapeutics - Oncology, Ocular Disorders, Respiratory
Disorders, Liver Diseases, Neuronal Disorders and Other
Therapeutics Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 49: Japan 16-Year Perspective for RNA Interference (RNAi)
by Therapeutics - Percentage Breakdown of Value Sales for
Oncology, Ocular Disorders, Respiratory Disorders, Liver
Diseases, Neuronal Disorders and Other Therapeutics for the
Years 2014, 2023 & 2030

CHINA
RNA Interference (RNAi) Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in China for 2023 (E)
Table 50: China Recent Past, Current & Future Analysis for RNA
Interference (RNAi) by Application - Drug Discovery &
Development, Therapeutics and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 51: China Historic Review for RNA Interference (RNAi) by
Application - Drug Discovery & Development, Therapeutics and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 52: China 16-Year Perspective for RNA Interference (RNAi)
by Application - Percentage Breakdown of Value Sales for Drug
Discovery & Development, Therapeutics and Other Applications
for the Years 2014, 2023 & 2030

Table 53: China Recent Past, Current & Future Analysis for RNA
Interference (RNAi) by Therapeutics - Oncology, Ocular
Disorders, Respiratory Disorders, Liver Diseases, Neuronal
Disorders and Other Therapeutics - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR

Table 54: China Historic Review for RNA Interference (RNAi) by
Therapeutics - Oncology, Ocular Disorders, Respiratory
Disorders, Liver Diseases, Neuronal Disorders and Other
Therapeutics Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 55: China 16-Year Perspective for RNA Interference (RNAi)
by Therapeutics - Percentage Breakdown of Value Sales for
Oncology, Ocular Disorders, Respiratory Disorders, Liver
Diseases, Neuronal Disorders and Other Therapeutics for the
Years 2014, 2023 & 2030

EUROPE
RNA Interference (RNAi) Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Europe for 2023 (E)
Table 56: Europe Recent Past, Current & Future Analysis for RNA
Interference (RNAi) by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR

Table 57: Europe Historic Review for RNA Interference (RNAi) by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 58: Europe 16-Year Perspective for RNA Interference
(RNAi) by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets for Years 2014, 2023 & 2030

Table 59: Europe Recent Past, Current & Future Analysis for RNA
Interference (RNAi) by Application - Drug Discovery &
Development, Therapeutics and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 60: Europe Historic Review for RNA Interference (RNAi) by
Application - Drug Discovery & Development, Therapeutics and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 61: Europe 16-Year Perspective for RNA Interference
(RNAi) by Application - Percentage Breakdown of Value Sales for
Drug Discovery & Development, Therapeutics and Other
Applications for the Years 2014, 2023 & 2030

Table 62: Europe Recent Past, Current & Future Analysis for RNA
Interference (RNAi) by Therapeutics - Oncology, Ocular
Disorders, Respiratory Disorders, Liver Diseases, Neuronal
Disorders and Other Therapeutics - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR

Table 63: Europe Historic Review for RNA Interference (RNAi) by
Therapeutics - Oncology, Ocular Disorders, Respiratory
Disorders, Liver Diseases, Neuronal Disorders and Other
Therapeutics Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 64: Europe 16-Year Perspective for RNA Interference
(RNAi) by Therapeutics - Percentage Breakdown of Value Sales
for Oncology, Ocular Disorders, Respiratory Disorders, Liver
Diseases, Neuronal Disorders and Other Therapeutics for the
Years 2014, 2023 & 2030

FRANCE
RNA Interference (RNAi) Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in France for 2023 (E)
Table 65: France Recent Past, Current & Future Analysis for RNA
Interference (RNAi) by Application - Drug Discovery &
Development, Therapeutics and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 66: France Historic Review for RNA Interference (RNAi) by
Application - Drug Discovery & Development, Therapeutics and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 67: France 16-Year Perspective for RNA Interference
(RNAi) by Application - Percentage Breakdown of Value Sales for
Drug Discovery & Development, Therapeutics and Other
Applications for the Years 2014, 2023 & 2030

Table 68: France Recent Past, Current & Future Analysis for RNA
Interference (RNAi) by Therapeutics - Oncology, Ocular
Disorders, Respiratory Disorders, Liver Diseases, Neuronal
Disorders and Other Therapeutics - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR

Table 69: France Historic Review for RNA Interference (RNAi) by
Therapeutics - Oncology, Ocular Disorders, Respiratory
Disorders, Liver Diseases, Neuronal Disorders and Other
Therapeutics Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 70: France 16-Year Perspective for RNA Interference
(RNAi) by Therapeutics - Percentage Breakdown of Value Sales
for Oncology, Ocular Disorders, Respiratory Disorders, Liver
Diseases, Neuronal Disorders and Other Therapeutics for the
Years 2014, 2023 & 2030

GERMANY
RNA Interference (RNAi) Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Germany for 2023 (E)
Table 71: Germany Recent Past, Current & Future Analysis for
RNA Interference (RNAi) by Application - Drug Discovery &
Development, Therapeutics and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 72: Germany Historic Review for RNA Interference (RNAi)
by Application - Drug Discovery & Development, Therapeutics and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 73: Germany 16-Year Perspective for RNA Interference
(RNAi) by Application - Percentage Breakdown of Value Sales for
Drug Discovery & Development, Therapeutics and Other
Applications for the Years 2014, 2023 & 2030

Table 74: Germany Recent Past, Current & Future Analysis for
RNA Interference (RNAi) by Therapeutics - Oncology, Ocular
Disorders, Respiratory Disorders, Liver Diseases, Neuronal
Disorders and Other Therapeutics - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR

Table 75: Germany Historic Review for RNA Interference (RNAi)
by Therapeutics - Oncology, Ocular Disorders, Respiratory
Disorders, Liver Diseases, Neuronal Disorders and Other
Therapeutics Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 76: Germany 16-Year Perspective for RNA Interference
(RNAi) by Therapeutics - Percentage Breakdown of Value Sales
for Oncology, Ocular Disorders, Respiratory Disorders, Liver
Diseases, Neuronal Disorders and Other Therapeutics for the
Years 2014, 2023 & 2030

ITALY
Table 77: Italy Recent Past, Current & Future Analysis for RNA
Interference (RNAi) by Application - Drug Discovery &
Development, Therapeutics and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 78: Italy Historic Review for RNA Interference (RNAi) by
Application - Drug Discovery & Development, Therapeutics and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 79: Italy 16-Year Perspective for RNA Interference (RNAi)
by Application - Percentage Breakdown of Value Sales for Drug
Discovery & Development, Therapeutics and Other Applications
for the Years 2014, 2023 & 2030

Table 80: Italy Recent Past, Current & Future Analysis for RNA
Interference (RNAi) by Therapeutics - Oncology, Ocular
Disorders, Respiratory Disorders, Liver Diseases, Neuronal
Disorders and Other Therapeutics - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR

Table 81: Italy Historic Review for RNA Interference (RNAi) by
Therapeutics - Oncology, Ocular Disorders, Respiratory
Disorders, Liver Diseases, Neuronal Disorders and Other
Therapeutics Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 82: Italy 16-Year Perspective for RNA Interference (RNAi)
by Therapeutics - Percentage Breakdown of Value Sales for
Oncology, Ocular Disorders, Respiratory Disorders, Liver
Diseases, Neuronal Disorders and Other Therapeutics for the
Years 2014, 2023 & 2030

UNITED KINGDOM
RNA Interference (RNAi) Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United Kingdom for 2023 (E)
Table 83: UK Recent Past, Current & Future Analysis for RNA
Interference (RNAi) by Application - Drug Discovery &
Development, Therapeutics and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 84: UK Historic Review for RNA Interference (RNAi) by
Application - Drug Discovery & Development, Therapeutics and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 85: UK 16-Year Perspective for RNA Interference (RNAi) by
Application - Percentage Breakdown of Value Sales for Drug
Discovery & Development, Therapeutics and Other Applications
for the Years 2014, 2023 & 2030

Table 86: UK Recent Past, Current & Future Analysis for RNA
Interference (RNAi) by Therapeutics - Oncology, Ocular
Disorders, Respiratory Disorders, Liver Diseases, Neuronal
Disorders and Other Therapeutics - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR

Table 87: UK Historic Review for RNA Interference (RNAi) by
Therapeutics - Oncology, Ocular Disorders, Respiratory
Disorders, Liver Diseases, Neuronal Disorders and Other
Therapeutics Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 88: UK 16-Year Perspective for RNA Interference (RNAi) by
Therapeutics - Percentage Breakdown of Value Sales for
Oncology, Ocular Disorders, Respiratory Disorders, Liver
Diseases, Neuronal Disorders and Other Therapeutics for the
Years 2014, 2023 & 2030

SPAIN
Table 89: Spain Recent Past, Current & Future Analysis for RNA
Interference (RNAi) by Application - Drug Discovery &
Development, Therapeutics and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 90: Spain Historic Review for RNA Interference (RNAi) by
Application - Drug Discovery & Development, Therapeutics and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 91: Spain 16-Year Perspective for RNA Interference (RNAi)
by Application - Percentage Breakdown of Value Sales for Drug
Discovery & Development, Therapeutics and Other Applications
for the Years 2014, 2023 & 2030

Table 92: Spain Recent Past, Current & Future Analysis for RNA
Interference (RNAi) by Therapeutics - Oncology, Ocular
Disorders, Respiratory Disorders, Liver Diseases, Neuronal
Disorders and Other Therapeutics - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR

Table 93: Spain Historic Review for RNA Interference (RNAi) by
Therapeutics - Oncology, Ocular Disorders, Respiratory
Disorders, Liver Diseases, Neuronal Disorders and Other
Therapeutics Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 94: Spain 16-Year Perspective for RNA Interference (RNAi)
by Therapeutics - Percentage Breakdown of Value Sales for
Oncology, Ocular Disorders, Respiratory Disorders, Liver
Diseases, Neuronal Disorders and Other Therapeutics for the
Years 2014, 2023 & 2030

RUSSIA
Table 95: Russia Recent Past, Current & Future Analysis for RNA
Interference (RNAi) by Application - Drug Discovery &
Development, Therapeutics and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 96: Russia Historic Review for RNA Interference (RNAi) by
Application - Drug Discovery & Development, Therapeutics and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 97: Russia 16-Year Perspective for RNA Interference
(RNAi) by Application - Percentage Breakdown of Value Sales for
Drug Discovery & Development, Therapeutics and Other
Applications for the Years 2014, 2023 & 2030

Table 98: Russia Recent Past, Current & Future Analysis for RNA
Interference (RNAi) by Therapeutics - Oncology, Ocular
Disorders, Respiratory Disorders, Liver Diseases, Neuronal
Disorders and Other Therapeutics - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR

Table 99: Russia Historic Review for RNA Interference (RNAi) by
Therapeutics - Oncology, Ocular Disorders, Respiratory
Disorders, Liver Diseases, Neuronal Disorders and Other
Therapeutics Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 100: Russia 16-Year Perspective for RNA Interference
(RNAi) by Therapeutics - Percentage Breakdown of Value Sales
for Oncology, Ocular Disorders, Respiratory Disorders, Liver
Diseases, Neuronal Disorders and Other Therapeutics for the
Years 2014, 2023 & 2030

REST OF EUROPE
Table 101: Rest of Europe Recent Past, Current & Future
Analysis for RNA Interference (RNAi) by Application - Drug
Discovery & Development, Therapeutics and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 102: Rest of Europe Historic Review for RNA Interference
(RNAi) by Application - Drug Discovery & Development,
Therapeutics and Other Applications Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 103: Rest of Europe 16-Year Perspective for RNA
Interference (RNAi) by Application - Percentage Breakdown of
Value Sales for Drug Discovery & Development, Therapeutics and
Other Applications for the Years 2014, 2023 & 2030

Table 104: Rest of Europe Recent Past, Current & Future
Analysis for RNA Interference (RNAi) by Therapeutics -
Oncology, Ocular Disorders, Respiratory Disorders, Liver
Diseases, Neuronal Disorders and Other Therapeutics -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 105: Rest of Europe Historic Review for RNA Interference
(RNAi) by Therapeutics - Oncology, Ocular Disorders,
Respiratory Disorders, Liver Diseases, Neuronal Disorders and
Other Therapeutics Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 106: Rest of Europe 16-Year Perspective for RNA
Interference (RNAi) by Therapeutics - Percentage Breakdown of
Value Sales for Oncology, Ocular Disorders, Respiratory
Disorders, Liver Diseases, Neuronal Disorders and Other
Therapeutics for the Years 2014, 2023 & 2030

ASIA-PACIFIC
RNA Interference (RNAi) Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Asia-Pacific for 2023 (E)
Table 107: Asia-Pacific Recent Past, Current & Future Analysis
for RNA Interference (RNAi) by Geographic Region - Australia,
India, South Korea and Rest of Asia-Pacific Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR

Table 108: Asia-Pacific Historic Review for RNA Interference
(RNAi) by Geographic Region - Australia, India, South Korea and
Rest of Asia-Pacific Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 109: Asia-Pacific 16-Year Perspective for RNA
Interference (RNAi) by Geographic Region - Percentage Breakdown
of Value Sales for Australia, India, South Korea and Rest of
Asia-Pacific Markets for Years 2014, 2023 & 2030

Table 110: Asia-Pacific Recent Past, Current & Future Analysis
for RNA Interference (RNAi) by Application - Drug Discovery &
Development, Therapeutics and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 111: Asia-Pacific Historic Review for RNA Interference
(RNAi) by Application - Drug Discovery & Development,
Therapeutics and Other Applications Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 112: Asia-Pacific 16-Year Perspective for RNA
Interference (RNAi) by Application - Percentage Breakdown of
Value Sales for Drug Discovery & Development, Therapeutics and
Other Applications for the Years 2014, 2023 & 2030

Table 113: Asia-Pacific Recent Past, Current & Future Analysis
for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular
Disorders, Respiratory Disorders, Liver Diseases, Neuronal
Disorders and Other Therapeutics - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR

Table 114: Asia-Pacific Historic Review for RNA Interference
(RNAi) by Therapeutics - Oncology, Ocular Disorders,
Respiratory Disorders, Liver Diseases, Neuronal Disorders and
Other Therapeutics Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 115: Asia-Pacific 16-Year Perspective for RNA

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06051396/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001